EPO announces its intention to approve patenting of AMP technology

Report this content

S2Medical AB (publ) (the "Company") has today received the information from the European Patent Office (EPO) that it intends to approve the patenting of the Company's AMP technology in Europe. This patent protection can, through a so-called unitary patent, provide patent protection in up to 25 European countries.


The patent application in question includes an antimicrobial peptide that has shown to significantly improve the efficiency of existing antibiotics and provide the opportunity for dismissed antibiotics to again be used, even when treating multi-resistant bacteria.


Antibiotic resistance is a global problem and alarmingly there is very little effort made to develop technologies that can end this problem. A very large proportion of maternal and child mortality is specifically linked to infections from bacteria’s resistant to antibiotics. Scientific studies have shown that if nothing is done about the situation, antibiotic resistance will result in 10 million deaths annually and is estimated to cost unimaginable 100-210 thousand billion USD annually globally.


"AMP technology is one of the biggest discoveries that the Company has contributed to and  the technology has an extremely great potential to be part of the solution to the problem that WHO refers to as the greatest threat to humanity's existence, antibiotic resistance. This harmonizes very well with our wound healing strategy, as wound infections probably is one of the main reasons why some wounds do not heal. Developing products in this segment is incredibly important and we hope that we can contribute to this topic being given more attention to put both S2Medical and Sweden on the map in that regard."  Said Petter Sivlér CEO of the Company



This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-10-2022 14:49 CET.

Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se 
E-mail: ca@vatorsec.se

About S2Medical 

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084


Documents & Links